Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Akili Inc (AKLI)
Akili Inc (AKLI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 32,107
  • Shares Outstanding, K 78,310
  • Annual Sales, $ 320 K
  • Annual Income, $ -7,960 K
  • 60-Month Beta 1.84
  • Price/Sales 96.98
  • Price/Cash Flow N/A
  • Price/Book 0.45
Trade AKLI with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.22
  • Most Recent Earnings -0.20 on 11/09/23
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 0.00% ( unch)
  • Historical Volatility 83.61%
  • IV Percentile 0%
  • IV Rank N/A
  • IV High 0.00% on N/A
  • IV Low 0.00% on N/A
  • Put/Call Vol Ratio N/A
  • Today's Volume N/A
  • Volume Avg (30-Day) N/A
  • Put/Call OI Ratio N/A
  • Today's Open Interest N/A
  • Open Int (30-Day) N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate -0.26
  • Number of Estimates 1
  • High Estimate -0.26
  • Low Estimate -0.26
  • Prior Year -0.62
  • Growth Rate Est. (year over year) +58.06%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2800 +32.14%
on 12/07/23
0.5100 -27.45%
on 12/04/23
-0.0600 (-13.95%)
since 11/10/23
3-Month
0.2800 +32.14%
on 12/07/23
1.0200 -63.73%
on 09/13/23
-0.5900 (-61.46%)
since 09/11/23
52-Week
0.2800 +32.14%
on 12/07/23
2.2000 -83.18%
on 02/09/23
-1.1800 (-76.13%)
since 12/09/22

Most Recent Stories

More News
Tech Startup Founders Unite in Chicago for Candid Conversation and Insights at the Founders Roundtable Event hosted by LeadrPro

/PRNewswire/ -- Calling all Founders, entrepreneurs, and visionaries! LeadrPro invites you to join us at the upcoming Founders Roundtable event in downtown...

AKLI : 0.3700 (-9.76%)
PureTech Founded Entity Akili Announces Adults with ADHD See Significant Improvements in Attention, ADHD Symptoms, and Quality of Life in Clinical Trial of Akili’s EndeavorRx® Video Game-Based Therapeutic

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company noted today that its Founded Entity, Akili, Inc. (Nasdaq: AKLI) (“Akili”),...

PRTC : 17.51 (-2.72%)
PRTC.LN : 140.000 (-0.28%)
AKLI : 0.3700 (-9.76%)
Adults with ADHD See Significant Improvements in Attention, ADHD Symptoms, and Quality of Life in Clinical Trial of Akili’s EndeavorRx® Video Game-Based Therapeutic

Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, today announced topline results of the STARS-ADHD-Adult clinical trial evaluating the efficacy and safety of EndeavorRx Ⓡ (AKL-T01) in...

AKLI : 0.3700 (-9.76%)
PureTech Announces Annual Results for Year Ended December 31, 2022

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”) today announces its results for the year ended December 31, 2022, as well as its cash balance as of the first quarter...

PRTC : 17.51 (-2.72%)
PRTC.LN : 140.000 (-0.28%)
BIIB : 246.28 (+2.92%)
KRTX : 204.56 (-0.45%)
VOR : 2.22 (+0.90%)
AKLI : 0.3700 (-9.76%)
Akili to Host First Quarter Financial Results Conference Call and Webcast on Thursday, May 11 at 4:30 p.m. ET

Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, will host a conference call and webcast to review its financial and operating results for the first quarter of 2023 on Thursday, May 11,...

AKLI : 0.3700 (-9.76%)
Akili Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, today reported its financial results for the quarter and full year ended December 31, 2022, and provided an update on business progress.

AKLI : 0.3700 (-9.76%)
Akili to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast on Tuesday, March 7 at 4:30 p.m. ET

Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, will host a conference call and webcast to review its financial and operating results for the fourth quarter and full year of 2022 on Tuesday,...

AKLI : 0.3700 (-9.76%)
Akili to Participate in the Cowen 43rd Annual Health Care Conference

Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, will participate in the Cowen 43 rd Annual Health Care Conference in Boston next month.

AKLI : 0.3700 (-9.76%)
Akili to Champion Digital Therapeutics in Conjunction with J.P. Morgan Healthcare Conference

Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, will participate in the Biotech Showcase and Solebury 1x1 Management Access Conference , both happening alongside the J.P. Morgan Healthcare...

AKLI : 0.3700 (-9.76%)
Pivotal Trial of EndeavorRxⓇ in Adolescents with ADHD Shows Robust Improvements in Attention and Broader Clinical Outcomes

Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, today announced topline results of the STARS-ADHD-Adolescents label expansion study evaluating the efficacy and safety of EndeavorRx Ⓡ...

AKLI : 0.3700 (-9.76%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Akili Interactive is a digital medicine company pioneering the development of cognitive treatments through game-changing technologies. The company's platform is powered by proprietary therapeutic engines designed to target cognitive impairment. Akili Interactive, formerly known as Roblox, is based in...

See More

Key Turning Points

3rd Resistance Point 0.4612
2nd Resistance Point 0.4406
1st Resistance Point 0.4253
Last Price 0.3700
1st Support Level 0.3894
2nd Support Level 0.3688
3rd Support Level 0.3535

See More

52-Week High 2.2000
Fibonacci 61.8% 1.4666
Fibonacci 50% 1.2400
Fibonacci 38.2% 1.0134
Last Price 0.3700
52-Week Low 0.2800

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar